Clinical Trials: Country-Specific Clinical Trials

Expanded Access and Compassionate Use in UK Clinical Trials

Posted on digi By digi

Expanded access and compassionate use programmes in the UK provide vital treatment options for patients who cannot enrol in trials. With frameworks such as EAMS and named patient supply, MHRA and HRA ensure that patient safety and ethical standards are maintained. Sponsors, CROs, and NHS Trusts must work together to overcome administrative challenges, integrate safety data, and maintain transparency. These programmes not only provide immediate patient benefit but also strengthen the evidence base for regulatory decision-making.
Click to read the full article.

Clinical Trials in UK, Country-Specific Clinical Trials

Post-Authorization Safety Studies in the EU

Posted on digi By digi

PASS requirements vary based on therapeutic area and product profile:

Oncology: Long-term follow-up PASS required for monitoring late-onset toxicities.
Rare Diseases: PASS leverage EU registries to capture data across dispersed patient populations.
ATMPs: Gene and cell therapies often require PASS extending over a decade to monitor delayed effects.
Pediatrics: PASS complement Pediatric Investigation Plans (PIPs) to ensure safety monitoring.

Click to read the full article.

Clinical Trials in EU, Country-Specific Clinical Trials

FDA Inspections of Phase 1 Clinical Units in the United States

Posted on digi By digi

Sponsors and Phase 1 units should: (1) maintain thorough informed consent processes; (2) ensure real-time safety monitoring; (3) validate EDC systems for Part 11 compliance; (4) maintain meticulous IP accountability; (5) conduct routine staff training; (6) audit CROs and vendors; (7) implement SOPs for protocol deviations; (8) conduct internal audits; (9) prepare inspection readiness binders; and (10) establish corrective and preventive action (CAPA) programs for identified deficiencies.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Clinical Trial Inspections in India: 483-like Observations

Posted on digi By digi

Clinical trial inspections in India are becoming more rigorous and aligned with global standards. Many observations now mirror FDA 483s, highlighting the need for improved site preparedness, data quality, and regulatory compliance. Sponsors, CROs, and investigators must collaborate to build robust systems that withstand regulatory scrutiny, ultimately ensuring ethical and scientifically sound trials for the Indian population and beyond.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

Post-Marketing Surveillance Trials in the UK

Posted on digi By digi

Post-marketing surveillance trials in the UK are essential for maintaining medicine safety and public trust beyond the point of authorisation. With MHRA oversight, HRA ethical governance, and NHS infrastructure, PMS studies generate crucial evidence for long-term safety, effectiveness, and real-world application. Sponsors, CROs, and investigators must adopt best practices in trial design, pharmacovigilance integration, and data quality management to meet regulatory expectations. As the UK advances its independent framework post-Brexit, PMS trials will continue to shape both patient safety outcomes and healthcare policy decisions.
Click to read the full article.

Clinical Trials in UK, Country-Specific Clinical Trials

FDA Clinical Data Submission Standards: CDISC and U.S. Trial Requirements

Posted on digi By digi

Sponsors should: (1) adopt CDISC standards early in trial design; (2) validate datasets with Pinnacle 21 before submission; (3) maintain traceability from raw data to analysis outputs; (4) ensure Define.xml completeness; (5) harmonize terminology across studies; (6) train staff in CDISC standards; (7) audit CRO deliverables; (8) integrate SEND into nonclinical workflows; (9) establish SOPs for data standardization; and (10) maintain documentation for FDA inspections.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Data Integrity Expectations in EU Clinical Research

Posted on digi By digi

Data integrity expectations vary based on trial type:

Oncology Trials: High data volume requires robust electronic systems and frequent monitoring.
Rare Diseases: Small sample sizes amplify the impact of any data discrepancy.
ATMPs: Long-term follow-up necessitates strong archiving practices and traceability.
Decentralized Trials: Dependence on digital tools requires additional validation and cybersecurity measures.

Click to read the full article.

Clinical Trials in EU, Country-Specific Clinical Trials

Site Accreditation Requirements for Indian Trials

Posted on digi By digi

While formal site accreditation is not currently a prerequisite in Indian clinical trials, growing regulatory expectations, global collaborations, and sponsor-driven feasibility assessments are making accreditation increasingly important. NABH standards, CDSCO site evaluations, and IEC compliance frameworks collectively shape a site’s readiness. Investing in infrastructure, training, and documentation systems today ensures long-term regulatory credibility and trial success tomorrow.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

MHRA Guidance on Decentralized Clinical Trials in the UK

Posted on digi By digi

Decentralized clinical trials in the UK reflect a broader shift toward patient-centric research and digital innovation. MHRA guidance encourages adoption while reinforcing GCP, data integrity, and patient safety. Sponsors, CROs, and NHS Trusts must carefully plan, validate, and document DCT elements to remain inspection-ready. By balancing flexibility with regulatory compliance, decentralized trials can expand access, reduce participant burden, and strengthen the UK’s role in global clinical research.
Click to read the full article.

Clinical Trials in UK, Country-Specific Clinical Trials

IND Maintenance During Ongoing Clinical Trials in the United States

Posted on digi By digi

Sponsors should: (1) establish SOPs for IND maintenance; (2) implement electronic systems for submission tracking; (3) perform regular compliance audits; (4) maintain updated investigator lists; (5) monitor safety signals continuously; (6) ensure consistency between IND and global submissions; (7) engage CROs with robust regulatory experience; (8) conduct staff training on IND obligations; (9) prepare inspection-ready records; and (10) document CAPA for identified deficiencies.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials